Cantor Fitzgerald initiated coverage of AbbVie with an Overweight rating and $200 price target. AbbVie has successfully positioned itself to absorb Humira biosimilar erosion and achieve modest operational revenue growth, which should be followed by a return to robust growth in 2025, the analyst tells investors in a research note. The firm thinks the peak sales potential of Skyrizi, Rinvoq, emraclidine as well AbbVie’s pipeline are underappreciated, and the tail for Humira will be manageable at $4B-$5B in annual sales.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- 3 Best Value Stocks to Buy in May 2024, According to Analysts
- AbbVie, Gilgamesh Pharmaceuticals to co-develop psychiatric disorder therapies
- Genmab reports Q1 revenue increased 46% vs. last year
- AbbVie price target lowered to $180 from $195 at BMO Capital
- AbbVie price target lowered to $191 from $196 at Morgan Stanley
